Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-04-03 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES STRATEGIC DECISIONS ON FXR AGONIST ASC42
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding strategic decisions on their FXR agonist ASC42, including discontinuation of certain clinical trials and reallocation of resources. It contains no financial statements or detailed financial data, nor is it a transcript or presentation. The document is relatively short (3460 characters) and serves to inform shareholders and investors about business development decisions. It is not an annual or interim report, audit report, or earnings release. It is not a regulatory filing or certification. The content fits best as a general regulatory announcement about business strategy and pipeline updates, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other categories.
2024-04-03 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities for Ascletis Pharma Inc., specifically focusing on changes in authorized and issued share capital, share options, repurchases, and cancellations for the month ended 31 March 2024. It is addressed to the Hong Kong Exchanges and Clearing Limited and follows a structured format typical of regulatory filings related to share capital movements. The content includes specific data on share repurchases and cancellations, share option schemes, and confirmations related to securities listed on the Stock Exchange of Hong Kong (SEHK). This type of document is not a financial report, earnings release, or management discussion but rather a regulatory disclosure about share capital changes and share transactions. It fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes such as share repurchases and cancellations. The document length (7142 characters) and detailed data confirm it is a substantive filing, not merely an announcement of a report or a certification. Therefore, the classification is SHA with high confidence.
2024-04-02 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 March 2024
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on authorized and issued share capital, share options, and confirmations related to securities issued by the company World Houseware (Holdings) Limited. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. The content is regulatory in nature, providing updates on share capital and share movements rather than financial performance, management changes, or earnings. It does not contain financial statements or management discussion but is a formal regulatory submission about share capital movements and confirmations. This fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories like capital changes (SHA) or director dealings (DIRS). The document is not a capital change announcement per se (no new shares issued or repurchased), but a monthly return on share capital movements and confirmations, which is a regulatory filing type.
2024-04-02 English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 100% confidence The document is titled 'RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023' and contains detailed audited consolidated financial statements including profit or loss, comprehensive income, financial position, segment information, notes on accounting policies, and amendments to financial reporting standards. The content is comprehensive and includes full financial data and analysis for the fiscal year ending December 31, 2023. This matches the characteristics of an Annual Report (10-K equivalent) rather than a short announcement or summary. The length of the document (15,000 characters) and the detailed financial statements confirm it is the full report, not just an announcement or a regulatory filing. Therefore, the appropriate classification is Annual Report (10-K). FY 2023
2024-03-26 English
ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS OF ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023' and contains detailed financial highlights including revenue, cost of sales, gross profit/loss, income, expenses, and loss per share for the full fiscal year 2023 with comparative figures for 2022. It also includes a comprehensive business review, pipeline updates, and management discussion and analysis sections. The length is substantial (15,000 characters), and the content includes audited condensed consolidated annual results, which are typical of an annual financial report. The document is not merely an announcement of a report or a certification but contains substantive financial data and analysis for the full fiscal year. Therefore, it fits the definition of an Annual Report (10-K). FY 2023
2024-03-25 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is an announcement from World Houseware (Holdings) Limited regarding the date of a board meeting scheduled to approve the release of the final results for the year ended 31 December 2023 and to consider the payment of a final dividend. The text does not contain the actual financial results or detailed report but only informs about the upcoming board meeting and the intention to release results. The document length is short (1750 characters) and it is clearly an announcement rather than the report itself. According to the rules, such announcements about the timing of report releases or board meetings are classified as Report Publication Announcements (RPA).
2024-03-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.